몰타 - 영어 - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 80 mg - lipid modifying agents

몰타 - 영어 - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin calcium, trihydrate - film-coated tablet - atorvastatin calcium trihydrate 30 mg - lipid modifying agents

몰타 - 영어 - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin calcium, trihydrate - film-coated tablet - atorvastatin calcium trihydrate 60 mg - lipid modifying agents

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 10.825mg equivalent to atorvastatin 10 mg - film coated tablet - 10 mg - active: atorvastatin calcium trihydrate 10.825mg equivalent to atorvastatin 10 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 21.65mg equivalent to atorvastatin 20 mg - film coated tablet - 20 mg - active: atorvastatin calcium trihydrate 21.65mg equivalent to atorvastatin 20 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 43.3mg equivalent to atorvastatin 40 mg - film coated tablet - 40 mg - active: atorvastatin calcium trihydrate 43.3mg equivalent to atorvastatin 40 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 86.6mg equivalent to atorvastatin 80 mg - film coated tablet - 80 mg - active: atorvastatin calcium trihydrate 86.6mg equivalent to atorvastatin 80 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium carbonate; hyprolose; microcrystalline cellulose; polysorbate 80; croscarmellose sodium; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 43.38 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; polysorbate 80; croscarmellose sodium; magnesium stearate; hyprolose; candelilla wax; calcium carbonate; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 21.69 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: candelilla wax; lactose monohydrate; croscarmellose sodium; polysorbate 80; hyprolose; magnesium stearate; calcium carbonate; microcrystalline cellulose; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.